PERSPECTIVE THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Payments to Acquire Debt Securities, Available-for-sale of $185.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-10
- PERSPECTIVE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $35.62M, a 19.95% decline year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $150.34M, a 565.09% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $20.61M, a 87.49% decline year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $32.13M.
- PERSPECTIVE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $119.84M, a 27.27% decline from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $164.78M.
- PERSPECTIVE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $185.95M 10-Q · filed 2026-08-10 | $206.56M derived: sum of 3 quarters · filed 2026-08-10 | $238.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $150.34M 10-Q · filed 2026-05-11 | $170.95M derived: sum of 2 quarters · filed 2026-05-11 | $203.08M derived: sum of 3 quarters · filed 2026-05-11 | $247.57M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $20.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $52.74M derived: sum of 2 quarters · filed 2026-03-16 | $97.23M derived: sum of 3 quarters · filed 2026-08-10 | $119.84M 10-K · filed 2026-03-16 |
| 2025-09-30 | $32.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $76.62M derived: sum of 2 quarters · filed 2026-08-10 | $99.22M 10-Q · filed 2025-11-10 | $264.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $44.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $67.09M 10-Q · filed 2026-08-10 | $231.87M derived: sum of 3 quarters · filed 2026-08-10 | $231.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $22.60M 10-Q · filed 2026-05-11 | $187.38M derived: sum of 2 quarters · filed 2026-05-11 | $187.38M derived: sum of 3 quarters · filed 2026-05-11 | $187.38M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $164.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $164.78M derived: sum of 2 quarters · filed 2026-03-16 | $164.78M derived: sum of 3 quarters · filed 2026-03-16 | $164.78M 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $0.00 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |